Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Targeting mitochondrial metabolism in CML

Vignir Helgason, PhD, University of Glasgow, Glasgow, UK, talks on dysregulated mitochondrial metabolism in chronic myeloid leukemia (CML), commenting on the potential of mitochondrial metabolism inhibitors as a novel therapeutic strategy in CML. Although experiments in cell lines and animal models have shown that such inhibitors are effective, it is necessary to reduce the toxicity of these compounds in order to evaluate them in clinical trials. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.